General Information of Drug (ID: DMEC8E2)

Drug Name
Anle138b Drug Info
Synonyms
Anle138b; 882697-00-9; Emrusolmin; ANLE-138b; 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1h-pyrazole; Emrusolmin [INN]; E7WRA77JET; 5-(1,3-benzodioxol-5-yl)-3-(3-bromophenyl)-1H-pyrazole; CHEMBL4748063; 3-(Benzo[d][1,3]dioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole; 1H-Pyrazole, 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-; Anle 138b; UNII-E7WRA77JET; Anle 138b; Anle-138b; SCHEMBL1660250; SCHEMBL21440048; BCP32558; Anle138b, >=98% (HPLC); BDBM50553260; MFCD30146410; NSC805132; s6782; AKOS037649277; CS-6522; DB13927; NSC-805132; BS-17773; HY-101855; D80685; EN300-331610; A858288; Z2327237898; 3-(1,3-dioxaindan-5-yl)-5-(3-bromophenyl)-1H-pyrazole
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 1 [1]
Cross-matching ID
PubChem CID
44608289
TTD Drug ID
DMEC8E2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Synuclein alpha (SNCA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RG7935 DME1YMX Parkinson disease 8A00.0 Phase 2 [3]
BIIB054 DMZO2SY Parkinson disease 8A00.0 Phase 2 [4]
PRX002 DMKTP8E Parkinson disease 8A00.0 Phase 2 [5]
TAK-341 DM6D30Q Multiple system atrophy 8D87.0 Phase 2 [6]
MEDI1341 DMQDBSU Parkinson disease 8A00.0 Phase 1 [4]
Posiphen R-phenserine DMCU54M Alzheimer disease 8A20 Phase 1 [7]
NPT200-11 DMFDBV5 Multiple system atrophy 8D87.0 Phase 1 [8]
SAR446159 DMWAO33 Parkinson disease 8A00.0 Phase 1 [9]
UCB7853 DMD7I23 Parkinson disease 8A00.0 Phase 1 [10]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Synuclein alpha (SNCA) TT08OSU SYUA_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04685265) A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of anle138b, and to Characterise the Effect of Food of anle138b in Mild to Moderate Parkinson's Disease. U.S.National Institutes of Health.
2 Anle138b interaction in alpha-synuclein aggregates by dynamic nuclear polarization NMR. Methods. 2023 Jun;214:18-27.
3 alpha-Synuclein in Parkinson's Disease. Cold Spring Harb Perspect Med. 2012 February; 2(2): a009399.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-alpha-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Oct 1;75(10):1206-1214.
6 Preclinical development of a high affinity alpha-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo. Neurobiol Dis. 2019 Dec;132:104582.
7 The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5 ntranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression. Parkinson's Disease Volume 2012 (2012), Article ID 142372, Page(13).
8 The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease. Sci Rep. 2018 Nov 1;8(1):16165.
9 Clinical pipeline report, company report or official report of Sanofi
10 ClinicalTrials.gov (NCT04651153) A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Healthy Male Study Participants and Multiple Ascending Doses in Patients With Parkinson's Disease. U.S.National Institutes of Health.